TickerTalks
Browse all tickers →
TickerTalks›$TVTX
TVTVTX

Travere Therapeutics, Inc.

Hot onWhy it's trendingX mentions rising faster than the marketMoving on elevated volumeStrong bullish X conversation
$TVTX·$5.8B·Biotechnology·Healthcare
$62.76-3.1%YTD+65.5%1Y+159.4%
Price updated 14h ago·X counts updated 6d ago
TVTVTX
$TVTXTravere Therapeutics, Inc.
$62.76-3.06%56 posts1.4×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $TVTX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

56X posts · last 7 days
Sep 1Sep 13
Chatter Meter
1.4×
QuietNormal · 1×Loud

How loud $TVTX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 87% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data40 posts analyzed · as of 2026-08-11

Travere Therapeutics posters cheer strong FILSPARI launch — US net product sales +96% YoY to $141M, 2,012 new PSFs received in Q2, and pegtibatinase HARMONY Phase 3 enrollment ongoing with 2H27 topline. JPMorgan upgrade with $90 PT and continued analyst PT raises heading into August. In-licensing of civorebrutinib expands the pipeline. Sentiment is decisively bullish.

Read what X is saying about $TVTX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $TVTX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-19

The move is getting stronger, with heavier trading behind it.

Travere is up 159% in twelve months on FILSPARI launch — with a $15M+ CEO-plus-officer insider-selling cluster on 9/17.

Travere Therapeutics is a rare-disease biotech commercializing FILSPARI (IgA nephropathy) and developing pegtibatinase for homocystinuria — a genuine commercial-launch story, and the tape has responded with a 159% T12M move.

  • Revenue grew 55.6% YoY last quarter to $127M with 94% gross margin — the four-quarter run of 56-162% growth confirms the FILSPARI launch is genuinely accelerating (2,012 new PSFs in Q2, US net product sales +96% YoY to $141M), and the last four EPS surprises came in wide (-175% to +190%).
  • JPMorgan upgraded with a $90 PT, and pegtibatinase HARMONY Phase 3 enrollment ongoing with 2H27 topline plus the in-licensing of civorebrutinib expands the pipeline — that's real catalyst path visibility.
  • CEO Dube printed $4.6M in insider sales on 9/17 plus officer Heerma combined ~$11M in M-Exempt-plus-S-Sale activity the same day — that's a ~$15M+ insider-selling cluster in a single day into the 87th percentile of range on 1.64x-average volume, which is the friction bulls should notice.

Oct 29 Q3 earnings — another 50%+ revenue print with clean FILSPARI new-PSF growth commentary extends the trade toward the JPM $90 target; a soft PSF-conversion print or a fresh insider-selling cluster is the invalidator on a name where the fundamentals are real but the CEO-plus-officer distribution is unusually heavy.

Agrees with X sentimentAgrees with the bullish X read on the strong FILSPARI launch — US net product sales +96% YoY to $141M, 2,012 new PSFs received in Q2, pegtibatinase HARMONY Phase 3 enrollment ongoing with 2H27 topline, and JPMorgan upgrade with $90 PT — all are load-bearing. The in-licensing of civorebrutinib adds real pipeline optionality. The ~$15M+ CEO-plus-officer insider-selling cluster on 9/17 is the friction the crowd is under-weighting into strength.

What to watch: Oct 29 Q3 earnings — another 50%+ revenue print with clean FILSPARI new-PSF growth commentary extends toward the JPM $90 target; a soft PSF-conversion print or fresh insider-selling cluster is the invalidator on a name where fundamentals are real but the CEO-plus-officer distribution is unusually heavy.

On the calendar: 2026-10-29 — Q3 earnings

Read the AI verdict on $TVTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Rare disease biotech with FILSPARI (sparsentan) approved for IgA nephropathy; also bile acid and metabolic disorder drugs.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TVTX.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

What this means for $TVTX

Partial — FILSPARI (sparsentan) dual-mechanism approval for IgA nephropathy and FSGS is a commercial rare-disease asset that benefits from the biotech multiple expansion, but no GLP-1/mRNA/gene-editing exposure; launch uptake trajectory is the primary driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+22.1%YTD
+42.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-236.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-13.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
9.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
94.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
3.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.37$-0.13-174.8%
Q1 2026May 4, 2026$-0.39$-0.30-30.0%
Q4 2025Feb 19, 2026$0.03$0.030.0%
Q3 2025Oct 30, 2025$0.28$-0.31+190.3%
Next earningsThu, Oct 29·consensus EPS $0.05

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$127.2M+55.6%79.0%-29.0%$-0.40$-62.5M
Q4 FY25$129.7M+73.4%98.0%-25.0%$-0.24$61.1M
Q3 FY25$164.9M+162.1%99.0%15.1%$0.29$14.2M
Q2 FY25$114.4M+111.5%98.7%-11.1%$-0.14$4.7M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$724.1M$691.0M – $781.9M-$0.03-$0.06 – $0.0411
FY27$1.1B$978.5M – $1.3B$3.16-$0.23 – $7.0011
FY28$1.4B$1.1B – $1.6B$4.52$2.26 – $7.6411
FY29$1.6B$1.4B – $1.9B$4.65$3.74 – $5.735
FY30$1.9B$1.6B – $2.3B$5.62$4.53 – $6.945

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.87%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+1.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+43.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 90.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.065-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 17Peter HeermaEVP, CHIEF COMMERCIAL OFFICER8.3K sh$539KSellSep 16William E. RoteChief Research Officer112.8K sh$7.1MSellSep 16Peter HeermaEVP, CHIEF COMMERCIAL OFFICER172.7K sh$11.0MSellSep 15William E. RoteChief Research Officer96.2K sh$6.0MSellSep 15Peter HeermaEVP, CHIEF COMMERCIAL OFFICER102.2K sh$6.4MSellSep 15Jula InrigEVP, Head of R&D & CMO44.7K sh$2.8MSellSep 15Elizabeth E ReedChief Legal Officer and GC37.5K sh$2.3MSellSep 10Jeffrey A MecklerDirector20.0K sh$1.3MSellSep 2Christopher R. ClineCFO642 sh$43KSellAug 18Gary A LyonsDirector5.0K sh$317K
1–10 of 23
+ 31 other (18 exempts · 12 awards · 1 gift) in window

See when $TVTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 98-K — Item 5.02: Officer or director change
AI summary

Travere Therapeutics disclosed on July 6, 2026 that Chief Accounting Officer and Principal Accounting Officer Sandra Calvin will retire following the filing of the company's annual Form 10-K, expected in February 2027. John Torell, CFA, CPA, current VP, Controller (at TVTX since 2021), is expected to succeed her in both roles, with board appointment expected before the Retirement Date to ensure an orderly transition. Planned multi-month leadership transition with a named internal successor; low operational disruption risk.

8-KOfficer or director changeJun 168-K — Item 5.02: Officer or director change
AI summary

Travere Therapeutics Chief Research Officer William Rote, Ph.D. provided notice on June 12, 2026 of his retirement effective February 17, 2027, the 10-year anniversary of his employment; he will remain in his current role and assist with transition through the Retirement Date. No successor CRO is named in the excerpt. Orderly planned departure with 8+ months of notice; the lengthy notice period suggests internal succession planning is underway, though the CRO role is material for a company mid-development on civorebrutinib and other pipeline assets.

8-KMaterial agreementJun 28-K — Item 1.01: Material agreement
AI summary

Travere Therapeutics entered a license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. on June 1, 2026 under which Everest grants Travere exclusive, royalty-bearing rights to develop and commercialize civorebrutinib (EVER001), a covalent reversible BTK inhibitor, in all fields across all countries outside China and certain East/Southeast Asian territories. Travere gains rights to make, import, distribute, sell, and develop the compound globally ex-Asia, with rights including a sublicense to third-party IP. Financial terms (upfront, milestones, royalties) are not disclosed in the excerpt. Material in-licensing deal — civorebrutinib adds a BTK inhibitor to Travere's pipeline, complementing its rare kidney disease focus, likely funded by the concurrent $525M convertible note raise.

8-KOfficer or director changeMay 218-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Travere Therapeutics held its 2026 Annual Meeting at which stockholders approved an amendment to the 2018 Equity Incentive Plan increasing the authorized share pool by 3,000,000 shares; this is disclosed under Item 5.02 as a compensatory arrangement approval. Item 5.07 covers the broader Annual Meeting voting results. Additional annual meeting proposals beyond the equity plan are described in the proxy but their vote outcomes are not fully detailed in the excerpt. The 3M share addition provides equity compensation runway; mildly dilutive.

8-KMaterial agreementMay 118-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 3.02: Unregistered equity sale · Item 8.01: Other event
AI summary

Travere Therapeutics completed a $525 million registered underwritten offering of 0.50% Convertible Senior Notes due May 15, 2032 on May 11, 2026, including $50M from full exercise of the underwriters' overallotment (underwriters: J.P. Morgan, Jefferies, Leerink Partners). Notes are redeemable at Travere's option from May 21, 2029 onward if the stock exceeds 130% of the conversion price; settlement in cash, shares, or a combination. Items 2.03/3.02 cover the debt creation and private placement aspects; Item 8.01 likely covers a concurrent capped call transaction to limit dilution above the conversion premium. A large-scale capital raise at low cost of debt — the $525M will fund pipeline development including the Everest BTK inhibitor license and commercial FILSPARI activities.

424B5Prospectus supplement (offering)May 7424B5
AI summary

Travere Therapeutics filed a 424B5 prospectus supplement for $475 million of 0.50% Convertible Senior Notes due May 15, 2032 at 100% issue price (with $50M underwriter greenshoe option). Conversion is permitted under specified stock price and trading triggers; notes are redeemable from May 21, 2029 onward if the stock exceeds 130% of the conversion price; settlement in cash, shares, or a combination at Travere's option. This is the pricing prospectus for the convertible offering, which was ultimately upsized to $525M following full exercise of the overallotment (see Job 45). The offering provides long-term capital at a low 0.50% coupon with dilution contingent on stock performance above the conversion premium.

424B5Prospectus supplement (offering)May 5424B5
AI summary

Travere Therapeutics filed an earlier 424B5 prospectus supplement for $400 million (with $60M greenshoe option) of convertible senior notes due 2032; the coupon and conversion price fields appear as blank placeholders in the excerpt, indicating this was a preliminary or term-pending filing before pricing was finalized. This preliminary prospectus was superseded by the final $475M pricing prospectus (Job 49) and the ultimately closed $525M offering (Job 45). Administrative/preliminary filing for Travere's convertible note offering process.

+ 17 other (7 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forumbusinesswire.com·2d agoBank of America Corp DE Invests $259.53 Million in Travere Therapeutics, Inc. $TVTXdefenseworld.net·2d agoTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com·8d agoHsbc Holdings PLC Sells 176,242 Shares of Travere Therapeutics, Inc. $TVTXdefenseworld.net·10d agoArtia Global Partners LP Buys New Shares in Travere Therapeutics, Inc. $TVTXdefenseworld.net·23d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $TVTX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport